Then, we asked whether high‐EDEM3 expression in tumour cells would affect the response to immunotherapy by analysing CRC patient responses to the PD‐1 antibody using the Gene Expression Omnibus (GSE236581). This evidence concerns the gene EDEM3 and neoplasm.